Datadog Option Alert: Apr 17 $135 Calls at the Ask: 2750 vs 615 OI

Datadog Option Alert: Apr 17 $135 Calls at the Ask: 2750 @ $3.44 vs 615 OI; Ref=$125.34

Datadog Option Alert: May 16 $135 Puts at the Bid: 1000 vs 1816 OI

Datadog Option Alert: May 16 $135 Puts at the Bid: 1000 @ $11.91 vs 1816 OI; Ref=$130.62

Datadog Option Alert: Apr 17 $140 Calls at the Ask: 1300 vs 449 OI; Earnings 2/13 Before Open 

Datadog Option Alert: Apr 17 $140 Calls at the Ask: 1300 @ $6.05 vs 449 OI; Earnings 2/13 Before Open Ref=$135.71

Datadog Option Alert: Apr 17 $140 Calls at the Bid: 1300 vs 449 OI; Earnings 2/13 Before Open 

Datadog Option Alert: Apr 17 $140 Calls at the Bid: 1300 @ $5.81 vs 449 OI; Earnings 2/13 Before Open Ref=$135.49

Datadog Option Alert: Mar 21 $120 Puts Sweep (56) below Bid!: 5500 vs 3161 OI; Earnings 2/13 Before Open 

Datadog Option Alert: Mar 21 $120 Puts Sweep (56) below Bid!: 5500 @ $1.332 vs 3161 OI; Earnings 2/13 Before Open Ref=$134.32

Datadog (NASDAQ:DDOG) 株価情報

DATADOG INC - CLASS A

Datadog

Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered via software as a service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of applications throughout their businesses.

Datadog Inc

WIIM

ARES

Shares of some banking and financial services stocks are trading higher as markets rebound following earlier weakness.

UBS analyst Steven Fisher downgrades Cummins (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NYSE">CMI</a>) from Buy to Sell and lowers the price target from $400 to $240.

News

Downgrades

Price Target

Analyst Ratings

UBS Downgrades Cummins to Sell, Lowers Price Target to $240

GameStop Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) has officially wandered into Wall Street's technical &#8220;danger zone.&#8221; A <a href="https://www.benzinga.com/topic/death-cross">dreaded Death Cross</a> has formed—when the 50-day moving average dips below the 200-day average—signaling a potentially bearish path ahead.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0407"><img loading="lazy" decoding="async" width="629" height="491" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07135649/Screenshot-2025-04-07-at-11.24.01-PM.png" alt="" class="wp-image-860517" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07135649/Screenshot-2025-04-07-at-11.24.01-PM.png 629w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07135649/Screenshot-2025-04-07-at-11.24.01-PM-300x234.png 300w" sizes="(max-width: 629px) 100vw, 629px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0407" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
But if you think this is game over for GameStop, think again.
Despite the grim chart pattern, CEO Ryan Cohen appears unfazed. Just last week, <a href="https://www.benzinga.com//node/44638041">he snapped up</a> 500,000 more shares, boosting his stake to 8.4%. 
That vote of confidence sent GME stock soaring 11% to $23.49, even as the broader market slumped.
Read Also: <a href="https://www.benzinga.com//node/44531398">Peter Schiff Slams Gamestop&#8217;s Bitcoin Strategy As Shares Plummet: &#8216;Now That All The Fools Have Already Rushed In, Smarter Investors Are Selling&#8217;</a>
<h2 class="wp-block-heading">Bearish Signs Everywhere &#8211; Except One</h2>
Technically, GME stock is looking rough. It's trading below its five, 20, 50 and 200-day exponential and simple moving averages. The MACD (moving average convergence/divergence) indicator is in negative territory, and the RSI (relative strength index) hovers at a neutral 51.58 &#8211; no clear momentum, just drifting.
Analysts call this setup &#8216;strongly bearish,&#8217; yet there's buying pressure. Enough, perhaps, to fuel a short-term bounce.
<h2 class="wp-block-heading">Bitcoin, Bonds, Bold Moves</h2>
Cohen's share grab followed <a href="https://colitco.com/gamestop-bitcoin-investment-convertible-bond-sale/">news</a> that GameStop has added Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) to its corporate investment strategy and plans to raise $1.3 billion via convertible bonds to fund that venture.
Investors initially cheered the crypto pivot, only to balk at the bond offering, sending the stock plunging by 25% before Friday's rebound.
With GME forming a Death Cross, bears may feel vindicated. But as Cohen doubles down and meme stock momentum stirs, traders might want to think twice before calling it quits. 
GameStop has a habit of turning chaos into opportunity, and right now, all eyes are on whether it can pull this off again.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com//node/44643100">Stocks Set To Continue Crashing After Worst Selloff Since 2020: Tariff Announcement Was &#8216;100% Smoot Hawley Disguised As Thoughtful Policy,&#8217; Says Expert</a></li>
</ul>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Gaming

Technicals

Markets

Tech

Trading Ideas

General

$BTC

GameStop Enters The Danger Zone: Death Cross Flashes, But Ryan Cohen Isn't Flinching

Shares of the Health Care Select Sector SPDR Fund (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NASDAQ">XLV</a>) are trading lower by 8.6% to $132.86 over the past week as tariff announcements from President Donald Trump last week spooked investors and <a href="https://www.benzinga.com/government/regulations/25/04/44670193/wall-street-turmoil-deepens-as-trump-threatens-massive-china-tariffs-bitcoin-wobbles-at-78k-whats-driving-markets-monday">dragged major sectors</a> of the market lower. 
While healthcare is often viewed as a defensive play during times of uncertainty, the <a href="https://www.benzinga.com/general/health-care">sector</a> is not immune to the broader economic implications of escalating trade tensions.
<h2 class="wp-block-heading">What Is XLV?</h2>
The Health Care Select Sector SPDR Fund is an exchange-traded fund that tracks the performance of the Health Care Select Sector Index, which includes large U.S. healthcare companies across pharmaceuticals, biotechnology, healthcare equipment and managed care. Top holdings include Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) .
Although healthcare demand tends to be less cyclical than sectors like industrials or energy, many of XLV's components are <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44667104/speculators-raise-wagers-on-fed-emergency-rate-cuts-as-theories-of-self-induced-crash-gather-pace">exposed to global markets</a>, supply chains and regulatory dynamics—all of which can be disrupted by a trade war.
Read Also: <a href="https://www.benzinga.com/news/25/04/44670684/whats-going-on-with-financial-select-sector-spdr-fund-xlf">What&#8217;s Going On With Financial Select Sector SPDR Fund (XLF)?</a>
<h2 class="wp-block-heading">Why Are Tariffs Hitting Healthcare—and XLV?</h2>
At first glance, healthcare might seem like an unlikely victim of tariff tensions, but the industry is more globally interconnected than it appears. Here's how tariff escalation is weighing on XLV and its underlying holdings:
<ul>
<li>Global Supply Chain Disruptions: Many medical devices and pharmaceutical ingredients are manufactured or sourced overseas. Tariffs on imported materials from countries like China can increase production costs for companies like Medtronic and Abbott Laboratories, which rely on <a href="https://www.benzinga.com/25/04/44663112/us-families-to-see-3800-annual-price-hike-says-experts-even-as-trump-indicates-tariff-windfall-of-tens-of-billions-of-dollars">international supply chains</a> to maintain margins and deliver products at scale. </li>
<li>Pricing Pressures Intensify: Healthcare companies already face intense political scrutiny over pricing. Tariffs add another <a href="https://www.benzinga.com/news/global/25/04/44668830/we-want-fairness-white-house-trade-adviser-navarro-says-trump-administration-is-focused-on-non-tariff-cheating">layer of cost inflation</a> that may be difficult to pass along to consumers or insurers. That's especially challenging for drugmakers and device manufacturers that operate under tight pricing regulations or depend on long-term contracts. </li>
<li>Global Growth Matters: Multinational pharmaceutical companies such as Pfizer and Johnson &amp; Johnson derive a significant share of their revenue from international markets. A slowdown in global economic growth due to <a href="https://www.benzinga.com/25/04/44661965/trumps-reciprocal-tariff-threat-wipes-out-nearly-18-trillion-from-magnificent-7-dan-ives-warns-it-could-set-us-tech-back-a-decade-investors-know-math-and-the-sad-reality">trade tensions</a> can dampen demand for branded drugs and medical products abroad, squeezing top-line growth. </li>
<li>Market Volatility Hits Sentiment: Even though healthcare is traditionally considered defensive, the sector is still susceptible to broader market moves. Investors often rotate out of equities—including healthcare—during times of heightened uncertainty. Additionally, biotech and life sciences stocks, many of which are included in XLV, tend to be more volatile and sensitive to shifts in investor risk appetite.</li>
</ul>
Read Also: <a href="https://www.benzinga.com/government/regulations/25/04/44670193/wall-street-turmoil-deepens-as-trump-threatens-massive-china-tariffs-bitcoin-wobbles-at-78k-whats-driving-markets-monday">Wall Street Turmoil Deepens As Trump Threatens Massive China Tariffs, Bitcoin Wobbles At $78K: What&#8217;s Driving Markets Monday?</a>

Why Health Care Select Sector SPDR Fund (XLV) Is Moving

UBS analyst Thomas Wadewitz maintains Allegiant Travel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGT#NASDAQ">ALGT</a>) with a Neutral and lowers the price target from $61 to $45.

ALGT

UBS Maintains Neutral on Allegiant Travel, Lowers Price Target to $45

<a href="https://www.wsj.com/tech/apple-iphone-production-china-tariffs-6cc37f40?mod=tech_lead_story" title="https://www.wsj.com/tech/apple-iphone-production-china-tariffs-6cc37f40?mod=tech_lead_story">https://www.wsj.com/tech/apple-iphone-production-china-tariffs-6cc37f40?mod=tech_lead_story</a>

AAPL

'Apple Plans to Source More iPhones From India as Potential Tariff Fix' -Wall Street Journal Report

UBS analyst Atul Maheswari maintains Frontier Group Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULCC#NASDAQ">ULCC</a>) with a Neutral and lowers the price target from $7 to $4.

ULCC

UBS Maintains Neutral on Frontier Group Holdings, Lowers Price Target to $4

UBS analyst Thomas Wadewitz maintains JetBlue Airways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) with a Sell and lowers the price target from $5 to $3.

JBLU

UBS Maintains Sell on JetBlue Airways, Lowers Price Target to $3

ANRO

Alto Neuroscience shares are trading higher after HC Wainwright & Co initiated coverage on the stock with a Buy rating and announced a $10 price target.

UBS analyst Thomas Wadewitz maintains Southwest Airlines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) with a Neutral and lowers the price target from $36 to $27.

UBS Maintains Neutral on Southwest Airlines, Lowers Price Target to $27

XRP's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) joined the broader crypto sell-off on Monday, tumbling 10% and sparking a <a href="https://in.benzinga.com/markets/cryptocurrency/25/04/44664914/bitcoin-ethereum-xrp-dogecoin-obliterate-142-billion-in-liquidations-plummet-up-to-16">wave of liquidations</a>. 
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>&nbsp;$1.88</td>
<td>$110.05 billion</td>
<td>-8%&nbsp;</td>
<td>-10.5%&nbsp;</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>&nbsp;$78,338.92</td>
<td>$1.55 trillion</td>
<td>-3.8%&nbsp;</td>
<td>-6%&nbsp;</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>&nbsp;$1,552.22</td>
<td>$187.3 billion</td>
<td>-8.6%&nbsp;</td>
<td>-15.7%&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto analyst Oscar Ramos <a href="https://x.com/realOscarRamos1/status/1909243845893562745">shared</a> his take on the current market chaos, noting he picked up XRP at $1.69 following its plunge to an intraday low of $1.61 — just before a modest bounce to $1.80. 
Though XRP remains under pressure and has lost key support near $2, Ramos said, "I bought the dip — not the mega dip at $1.61, but at least I got $1.69."
He also flagged broader macro headwinds, citing the NASDAQ opening under 15,000.
Speculation is swirling over the possibility of an emergency rate cut to counter accelerating market declines. Ramos posed the question many are asking: &#8220;Can the Fed do an emergency cut to slow the pain of the crashing in the world right now?&#8221;
Statistics: XRP's sharp drop pushed long liquidations to $41.1 million in the past 24 hours — the highest since March 3, 2025, according to Coinglass data. Short liquidations also surged to $19.32 million, marking the highest level since March 2.
XRP derivatives trading volume exploded by 587% in the same period, highlighting the heightened activity amid extreme volatility.
Whale Alert data <a href="https://x.com/whale_alert/status/1909182445431271932">shows</a> that 200 million XRP—valued at $355.6 million—was moved from an unknown wallet to Binance, sparking speculation that whales might have insider knowledge the broader market lacks.
Community News: Despite short-term price pressure, Ripple's latest <a href="https://ripple.com/ripple-press/global-financial-infrastructure-entering-a-new-era/">report</a> predicts strong long-term fundamentals for XRP. It forecasts that the tokenized real-world asset market could grow from $0.6 trillion today to $9.4 trillion by 2030 — and even hit $18.9 trillion by 2033.
The projected 53% CAGR will be driven by XRP and Ripple's stablecoin RLUSD, with growth unfolding in three key stages: low-risk adoption, institutional expansion and full market transformation.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44647456/bitcoin-xrp-diversion">Bitcoin Consolidates, But XRP May Have Topped: What&#8217;s Driving This Diversion?</a></li>
</ul>
Image: Shutterstock

$ETH

$XRP

XRP Down 10% In A Single Day: Is The Worst Over?

UBS analyst Thomas Wadewitz maintains American Airlines Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) with a Neutral and lowers the price target from $13 to $9.

UBS Maintains Neutral on American Airlines Group, Lowers Price Target to $9

HC Wainwright initiated coverage on Ionis Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>), a commercial-stage biotech company focused on <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">RNA-targeted therapeutics</a>.
Analyst Mitchell Kapoor says Ionis has used its RNA technology to develop a wide range of drugs. The analyst believes Ionis has built a strong and valuable platform with drug opportunities that carry less risk thanks to its track record of success in clinical trials, regulatory approvals, and commercial launches over the next few years, all supported by strong cash flow.
In addition to its major programs, Kapoor highlights Ionis&#8217; promising early-stage projects in the pipeline.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44276870/ionis-pharmaceuticals-partners-with-japan-based-ono-pharmaceutical-for-rare-blood-disease-drug-in-over-800-million-deal" rel="noreferrer noopener">Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal</a>
&#8220;The company's pipeline depth has allowed for constant business development to support the growth of the company as well as continued research and development,&#8221; Kapoor writes.
HC Wainwright initiated with a Buy rating and a <a target="_blank" href="https://www.benzinga.com/quote/IONS/analyst-ratings" rel="noreferrer noopener">price target of $45</a>.
Ionis already has several approved drugs. The spotlight is now shifting to new product launches and important clinical trial results expected in 2025 and 2026. Two drugs worth noting:
<ul>
<li><a href="https://www.benzinga.com/24/12/42613640/fda-approves-ionis-pharmaceuticals-rare-genetic-disease-therapy-to-lower-high-level-of-fat-in-blood" target="_blank" rel="noreferrer noopener">Tryngolza (olezarsen)</a>, aimed at lowering triglycerides. Two major Phase 3 trial results are expected in the second half of 2025 for treating severe hypertriglyceridemia (sHTG). These results are seen as a key growth opportunity. Analyst Kapoor adds that if successful, and if the drug is approved for sHTG, Ionis would fully control U.S. sales and have strong international rights as well. The U.S. market alone includes about 2.3 million patients.</li>
<li>Wainua (eplontersen), used to treat transthyretin-mediated amyloidosis (ATTR).</li>
</ul>
HC Wainwright sees potential FDA approval (PDUFA date of Aug. 21) for donidalorsen in hereditary angioedema (HAE) as a <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/39118220/ionis-pharmaceuticals-reveals-late-stage-donidalorsen-data-analyst-says-results-sho" target="_blank" rel="noreferrer noopener">near-term stock driver</a>.
&#8220;We think the market does not fully appreciate the potential for differentiation, given a far less-frequent dosing regimen for donidalorsen vs. SOC,&#8221; the analyst writes.
Ionis said 2024 revenue of $705 million exceeded guidance as the company continued to generate revenue from diverse sources. The company added new revenue sources in 2024 with the launch of Wainua and Tryngolza <a href="https://www.benzinga.com/25/02/43818962/ionis-pharmaceuticals-says-2024-revenue-exceeds-guidance-on-sales-from-diverse-sources-forecasts-over-600-million-in-2025-sales">in the U.S.</a>
Price Action: IONS stock is down 0.33% at $27 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44670067/anavex-life-sciences-long-term-trial-data-for-blarcamesine-treatment-slows-cognitive-and-functional-decline-in-alzheimers-patients" target="_blank" rel="noreferrer noopener">Anavex Life Sciences Reports Prolonged Benefit Data Of Blarcamesine In Early Alzheimer&#8217;s Over 3 Years</a></li>
</ul>
Image: Shutterstock

Analyst Color

Biotech

Health Care

Initiation

IONS

Drugmaker Ionis Pharmaceuticals Garners Analyst Praise For 'Pipeline Depth'

UBS analyst Steven Fisher downgrades Caterpillar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) from Neutral to Sell and lowers the price target from $385 to $243.

UBS Downgrades Caterpillar to Sell, Lowers Price Target to $243

AMAT

INDI

KLAC

LRCX

MCHP

NVDA

SMCI

TSEM

Shares of chip stocks are trading higher amid overall market volatility. Stocks across sectors have been volatile on Monday, with tech stocks rebounding following earlier weakness.

ZBAO

Zhibao Technology Shares Resumed Trade

UBS analyst Steven Fisher downgrades Martin Marietta Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLM#NYSE">MLM</a>) from Buy to Neutral and announces $491 price target.

UBS Downgrades Martin Marietta Materials to Neutral, Announces $491 Price Target

The market just slipped through what JPMorgan&#8217;s Jason Hunter calls a "fork in the road" — only this time, it&#8217;s more like tumbling through a black hole. Hunter says the recent U.S. trade policy surprise pushed <a href="https://www.benzinga.com/topic/s-p-500">the S&amp;P 500</a> index below a critical level near 5500, triggering what could be an accelerated pricing of recession risks.
<h1 class="wp-block-heading">Key Support Breached – Now What?</h1>
Hunter highlights that the S&amp;P 500 didn't just tiptoe past support — it gapped straight through 5500, dipped through the mid-5300s and now hovers near a major support zone in the low 5100s.
He believes a bounce is possible from here, but don't bet the house on it. "We suspect the market can stage a bear market rebound&#8230; but believe that lift will be contained and potentially short-lived unless the news flow sees a dramatic change," he warns.
Read Also: <a href="https://www.benzinga.com/markets/equities/25/04/44660697/how-to-protect-against-a-1987-style-s-p-500-crash-scenario">How to Protect Against A 1987-Style S&amp;P 500 Crash Scenario</a>
<h1 class="wp-block-heading">The Yield Curve Has Its Own Drama</h1>
In the bond world, the 2-year Treasury note flirted with resistance at 3.48%-3.55% before backing off. Hunter now sees a ceiling at 3.825%-3.85%, but expects an eventual bullish breakout — translation: yields may start rising again soon.
<h1 class="wp-block-heading">How To Play It</h1>
For those looking to trade this technical twist, ETFs like the SPDR S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), which tracks the S&amp;P 500, or the ProShares UltraShort S&amp;P500 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SDS#NYSE">SDS</a>), leveraged inverse ETF for the S&amp;P 500, offer exposure. If you're watching yields, the iShares 1-3 Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHY#NASDAQ">SHY</a>), a 1–3 Year Treasury ETF, or the iShares 3-7 Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IEI#NASDAQ">IEI</a>), a 3–7 Year Treasury ETF, could be in focus.
The bottom line? 
The S&amp;P 500 just slipped past a critical technical threshold, and while a short bounce may lure some in, Hunter's charts are flashing caution. Don&#8217;t mistake this for a reset — it&#8217;s more likely the eye of the storm.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/econ-s/25/04/44669291/sp-500-officially-sinks-into-bear-market-heres-what-investors-need-to-know">S&amp;P 500 Officially Sinks Into Bear Market: Here&#8217;s What Investors Need To Know</a></li>
</ul>
Photo: Shutterstock

Broad U.S. Equity ETFs

ETFs

iShares Trust Barclays 1-3 Year Treasury Bond Fund

S&P 500 Slips Through The Cracks, Analyst Spots Short-Lived Bounce Before Gravity Kicks In

Zhibao Technology Shares Resume Trade

In the preceding three months, 19 analysts have released ratings for First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>), presenting a wide array of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">9</td>
<td align="right">9</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">4</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $259.32, a high estimate of $335.00, and a low estimate of $209.00. Highlighting a 8.01% decrease, the current average has fallen from the previous average price target of $281.89. 
<img src="https://www.benzinga.com/files/images/story/2025/1744048873_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The perception of First Solar by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;---------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Joseph Osha &#x7C;Guggenheim &#x7C;Lowers &#x7C;Buy &#x7C; $253.00&#x7C;$304.00 &#x7C; 
&#x7C;Jordan Levy &#x7C;Truist Securities &#x7C;Lowers &#x7C;Buy &#x7C; $245.00&#x7C;$285.00 &#x7C; 
&#x7C;Christine Cho &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $236.00&#x7C;$273.00 &#x7C; 
&#x7C;Joseph Osha &#x7C;Guggenheim &#x7C;Lowers &#x7C;Buy &#x7C; $304.00&#x7C;$335.00 &#x7C; 
&#x7C;Andrew Percoco &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Overweight &#x7C; $238.00&#x7C;$297.00 &#x7C; 
&#x7C;Jon Windham &#x7C;UBS &#x7C;Lowers &#x7C;Buy &#x7C; $285.00&#x7C;$360.00 &#x7C; 
&#x7C;Kashy Harrison &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Overweight &#x7C; $230.00&#x7C;$250.00 &#x7C; 
&#x7C;Philip Shen &#x7C;Roth MKM &#x7C;Maintains &#x7C;Buy &#x7C; $280.00&#x7C;$280.00 &#x7C; 
&#x7C;Christopher Dendrinos&#x7C;RBC Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $251.00&#x7C;$280.00 &#x7C; 
&#x7C;Mark Strouse &#x7C;JP Morgan &#x7C;Lowers &#x7C;Overweight &#x7C; $268.00&#x7C;$282.00 &#x7C; 
&#x7C;Ameet Thakkar &#x7C;BMO Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $230.00&#x7C;$260.00 &#x7C; 
&#x7C;Jordan Levy &#x7C;Truist Securities &#x7C;Lowers &#x7C;Buy &#x7C; $285.00&#x7C;$300.00 &#x7C; 
&#x7C;Vikram Bagri &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $236.00&#x7C;$254.00 &#x7C; 
&#x7C;Maheep Mandloi &#x7C;Mizuho &#x7C;Raises &#x7C;Outperform &#x7C; $259.00&#x7C;$218.00 &#x7C; 
&#x7C;Julien Dumoulin-Smith&#x7C;B of A Securities &#x7C;Lowers &#x7C;Buy &#x7C; $236.00&#x7C;$246.00 &#x7C; 
&#x7C;Christine Cho &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $273.00&#x7C;$275.00 &#x7C; 
&#x7C;Joseph Osha &#x7C;Guggenheim &#x7C;Maintains &#x7C;Buy &#x7C; $335.00&#x7C;$335.00 &#x7C; 
&#x7C;Tom Curran &#x7C;Seaport Global &#x7C;Announces &#x7C;Buy &#x7C; $274.00&#x7C;- &#x7C; 
&#x7C;Michael Blum &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $209.00&#x7C;$240.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to First Solar. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of First Solar compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of First Solar's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into First Solar's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FSLR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on First Solar analyst ratings.</a>
<h2>Discovering First Solar: A Closer Look</h2>
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and India.
<h3>First Solar's Financial Performance</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: First Solar's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 30.68%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: First Solar's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 25.96%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): First Solar's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 5.05%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 3.34%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: First Solar's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.09.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Date	Put/Call	Strike Price	Exp Date	DTE	Trade Vol	Day Vol	Vol / OI	OI	Trade Type	Sentiment
12:09 PMFeb 20, 2025	CALL	$135.00	Apr 17, 2025	9	207	2750	34	615	TRADE	BULLISH
02:28 PMFeb 14, 2025	PUT	$135.00	May 16, 2025	38	1016	1000	56	1816	TRADE	BULLISH
03:39 PMFeb 13, 2025	CALL	$140.00	Apr 17, 2025	9	3020	1300	673	449	TRADE	BULLISH
03:35 PMFeb 13, 2025	CALL	$140.00	Apr 17, 2025	9	1720	1300	383	449	TRADE	BEARISH
09:33 AMFeb 13, 2025	PUT	$120.00	Mar 21, 2025	-18	5508	5500	174	3161	SWEEP	BULLISH

Comments

Datadog

Unusual Options Activity for

ニュース

パートナーシップ

ベンジンガ・グローバル